Neovasc (NVCN) Outpaces Q4 Loss Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Canaccord Genuity Cuts Price Target on Neovasc (NVCN) to $9.50; Reiterates Buy
March 30, 2016 10:04 AM EDTCanaccord Genuity maintained a Buy rating on Neovasc (NASDAQ: NVCN), and cut the price target to $9.50 (from $15.00). Cannaccord continues to see NVCN as an attractive long-term asset in the potentially huge Transcatheter mitral valve replacement (TMVR) space. However, clinical and market development hurdles remain for all, and enrollment in NVCNs TIARA-1... More
